Plan B, the most well-known morning-after pill in the country, is becoming more popular among women since the Supreme Court in June overruled Roe v. Wade, the legal decision that granted Americans the right to an abortion.
Plan B is not always available even if it is sold over the counter. Many people with modest incomes find it to be too pricey at an average cost of $40–$50. Pharmacies are permitted to refuse to dispense it in some states, and shops frequently store the substance out of consumers’ reach.
Now, Plan B might be subject to even more limitations. In order to obtain approval for Plan B’s over-the-counter status, the Food and Drug Administration required that the product’s label include a warning that it “may prevent a fertilised egg from attaching to the womb.” However, scientists and medical experts argue that this statement is not supported by scientific evidence. Medical experts disagree with the anti-abortion campaigners who claim that any intervention with an egg constitutes an abortion.
Justice Clarence Thomas proposed that the Supreme Court reconsider its earlier opinion on contraceptives in the wake of the court’s decision. For the brand and its customers, unclear label language might spell trouble. What then is Plan B’s outlook for the future?